Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy of autologous tumor lysate-pulsed dendritic and cytokine-induced killer cells (DC-CIK) for colorectal cancer (CRC).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shenzhen Hornetcorn Bio-technology Company, LTD
• Collaborator: Jingzhou Central Hospital

Criteria

Inclusion Criteria:

• 18~80 years old;

• Histologically confirmed with colorectal cancer at stage Ⅰ~Ⅲ;

• Patients who can accept curative operations;

• Patients who have a life expectancy of at least 3 months;

• Eastern Cooperative Oncology Group (ECOG) performance status was 0 - 1.

Exclusion Criteria:

• Hemoglobin<8.0 g/dL,Platelet count <75 x 10^9/L; ALT, AST, BUN and Cr more than normal limits on 3.0 times ;

• Known or suspected allergy to the investigational agent or any agent given in association with this trial;

• Pregnant or lactating patients;

• Known history of Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) or TreponemaPallidun (TP) infection;

• Patients who are suffering from serious autoimmune disease;

• History of organ allograft;

• Patients who had distant metastases;

• Patients who had active infection;

• Prior use of any anti-cancer treatment in 30 days;

• Now or recently will join another experimental clinical study ;

• Other situations that the researchers considered unsuitable for this study.